Aadil Rasheed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aadil Rasheed has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ali Sunyaev
Technische Universität München, Heilbronn, Deutschland
2 shared publications - Andreas Schimanski
PIRCHE AG, Research and Development, Berlin, Germany
2 shared publications - Danilo Schmidt
Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany
2 shared publications - Florian Leiser
Karlsruhe Institute of Technology
2 shared publications - Franz Fenninger
Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
2 shared publications - Héloïse Cardinal
Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada
2 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
The AIR·MS data platform for artificial intelligence in healthcare
Objective: To present the Artificial Intelligence-Ready Mount Sinai (AIR·MS) platform-unified access to diverse clinical datasets from the Mount Sinai Health System (MSHS), along with computational infrastructure for AI-driven research and demonstrate its utility with 3 research projects. Materials and Methods: AIR·MS integrates structured and unstructured data from multiple MSHS sources via the OMOP Common Data Model on an in-memory columnar database. Unstructured pathology and radiology data are integrated through metadata extracted from and linking the raw source data. Data access and analytics are supported from the HIPAA-compliant Azure cloud and the on-premises Minerva High-Performance Computing (HPC) environment. Results: AIR·MS provides access to structured electronic health records, clinical notes, and metadata for pathology and radiology images, covering over 12M patients. The platform enables interactive cohort building and AI model training. Experimentation with complex cohort queries confirm a high system performance. Three use cases demonstrate, risk-factor discovery, and federated cardiovascular risk modeling. Discussion: AIR·MS demonstrates how clinical data and infrastructure can be integrated to support large-scale AI-based research. The platform’s performance, scale, and cross-institutional design position it as a model for similar initiatives. Conclusion: AIR·MS provides a scalable, secure, and collaborative platform for AI-enabled healthcare research on multimodal clinical data.
- 3 November 2025
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 8 (6)
Open AccessThe AIR·MS data platform for artificial intelligence in healthcare
Objective: To present the Artificial Intelligence-Ready Mount Sinai (AIR·MS) platform-unified access to diverse clinical datasets from the Mount Sinai Health System (MSHS), along with computational infrastructure for AI-driven research and demonstrate its utility with 3 research projects. Materials and Methods: AIR·MS integrates structured and unstructured data from multiple MSHS sources via the OMOP Common Data Model on an in-memory columnar database. Unstructured pathology and radiology data are integrated through metadata extracted from and linking the raw source data. Data access and analytics are supported from the HIPAA-compliant Azure cloud and the on-premises Minerva High-Performance Computing (HPC) environment. Results: AIR·MS provides access to structured electronic health records, clinical notes, and metadata for pathology and radiology images, covering over 12M patients. The platform enables interactive cohort building and AI model training. Experimentation with complex cohort queries confirm a high system performance. Three use cases demonstrate, risk-factor discovery, and federated cardiovascular risk modeling. Discussion: AIR·MS demonstrates how clinical data and infrastructure can be integrated to support large-scale AI-based research. The platform’s performance, scale, and cross-institutional design position it as a model for similar initiatives. Conclusion: AIR·MS provides a scalable, secure, and collaborative platform for AI-enabled healthcare research on multimodal clinical data.
- Open Access
- 22 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48892
NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study
Background: Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. Objective: The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. Methods: To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. Results: We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. Conclusions: For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/48892
- 22 December 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48892
Open AccessNephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study
Background: Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. Objective: The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. Methods: To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. Results: We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. Conclusions: For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/48892
- Open Access
- 10 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint)
BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. METHODS To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. RESULTS We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. CONCLUSIONS For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892
- 10 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessNephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint)
BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. METHODS To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. RESULTS We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. CONCLUSIONS For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892